Roche's Lebrikizumab Shows Potential For Biomarker Targeting In Asthma
Phase II data published in NEJM show that biomarker-assisted therapies could be valuable in targeting the variabilities of the disease.
Phase II data published in NEJM show that biomarker-assisted therapies could be valuable in targeting the variabilities of the disease.